The box-plot analysis was performed using SigmaPlot version 10. 0 software (Systat Software Chloroxylenol Inc., San Jose, CA, USA). == Abbreviations == colony-forming models a genetically detoxified form of diphtheria toxin invasive pneumococcal disease interquartile range 50% lethal dose opsonophagocytic killing assay 13-valent pneumococcal conjugate vaccine pneumococcal polysaccharide enzyme-linked immunosorbent assay quartile == Disclosure of potential conflicts of interest == D. G. L. and the range of anti-capsular IgG in the population. Challenge of wild-type or neutropenic mice with serotypes three or more, 5, 6A, 6B, and 9V showed protective immunity despite of induced relatively low levels of anti-capsular antibodies. With comparison analysis, a mouse model should be adequate to get evaluating serological efficacy and difference in the population level as preclinical trial. KEYWORDS: pneumococcal conjugate vaccine, Mouse model, Neutropenic infection model, serological evaluation, protection efficacy, Streptococcus pneumoniae == Intro == Streptococcus pneumoniae is an opportunistic pathogen that colonises the upper respiratory tract asymptomatically. 1It can invade the bloodstream and cause systemic diseases such as sepsis, meningitis, and invasive pneumonia. 2, 3Mortality rates PITX2 to get invasive pneumococcal disease (IPD) are particularly high in high-risk populations; e. g. young children, the elderly, and immunocompromised patients. At least 1 million children <5 y of age die annually from Chloroxylenol pneumonia and IPD in developing countries. 4 To prevent pneumococcal disease, the pneumococcal polysaccharide vaccine (PPV23), which comprises 23 capsular serotypes and is effective in healthy adults, was first licensed in 1983. 5, 6However, as PPV23 is poorly immunogenic in children, the elderly, and immunocompromised individuals, 7-9the 7-valent pneumococcal conjugate vaccine (PCV7), which comprises the 14, 6B, 19F, 23F, 18C, 4, and 9V polysaccharide antigens conjugated to a carrier protein, was developed, as well as efficacy continues to be demonstrated. 10-13However, the incidence of IPD caused by serotypes included in the PCV7 vaccine offers decreased, 14-16while that of IPD due to non-PCV7 serotypes has increased. 17, 18This has led to the development and licensing of higher-valency pneumococcal conjugate vaccines (PCV10-PCV7 plus serotypes 1, 5, and 7F; and PCV13-PCV10 plus Chloroxylenol serotypes 3, 6A, and 19A) for prevention of pneumococcal diseases. Creature models possess played an important role in vaccine development. Although dedication of vaccine efficacy using animal versions is subject to several limitations (strains non-pathogenic in animals, etc . ), use of creature models to get vaccine study facilitates their translation to clinical use. 19In particular, the mouse model is more economical and convenient than other animal versions and continues to be used in previous studies to demonstrate the immunogenicity and protecting efficacy of S. pneumoniae vaccines. 20-22Also, because more individuals in mouse model could be reared in limited area and involved in the experiment than other creature model, populace study in a mouse model should be possible for investigating the person difference and variation in the progress of vaccine evaluating. In developing country, vaccine development is still needed in economical aspect, as high cost of previously licensed vaccine is a barrier to the people. The aim of this study is to assess mouse model as a preclinical platform in development of pneumococcal vaccine by comparative analysis. It was assessed whether a mouse model might be effective for evaluating the efficacy of higher-valency pneumococcal conjugate vaccines including polysaccharide antigens of H. pneumoniae strains nonpathogenic against mouse. To get comparative analysis, a recently patented 13-valent pneumococcal capsular vaccine by a South Korean manufacturer (Patent No . WO 2013191459 A1) and licensed PCV13 were used because assessment components. Moreover, we described the range of an individual difference in the serological immunogenicity of mouse population, compare with that of previously licensed PCV13 as a control. It was expected that the comparative evaluation in animal populace should compensate for the drawbacks of evaluating new vaccine in a mouse model. == Results == == Determination of cut-off values and immunization method == The PnP ELISA cut-off value of each serotype calculated using sera from 20 non-immunised mice was A405 =0. 1420. 204 (Table 1). For the determination of immunization method, the anti-capsular IgG level was screened in mice (n = 3 per each group) immunised s. Chloroxylenol c., i. p., and i. m. with three doses of each vaccine (new PCV13 and control vaccine). The no-diluted serum level of IgG against serotypes 5 (A405= 0. 132), 7F (A405= 0. 19), and 23F (A405=.